Image For Activity Cover
2021 Annual Global Meeting: Virtual
Includes master and plenary sessions.

Fully virtual event, held August 30 - September 2, 2021
Course includes master and plenaries sessions, see information for sessions below. 

Speaker & Presentation Information

Master Session: Cervical Cancer
Gonzalo Giornelli Case #1: Prevention & Staging
Laia Bruni a) How do we get to eradication? b) Is”catch up vaccination “ worthy in older than teen-agers? Is it the soluction for “vulnerable economies”?
Gonzalo Giornelli Staging
Ingfrid S. Haldorsen a) PET/CT VS MRI to stage LRACC: PRO’S AND CON’S b) Should we rely on imaging for pre surgical staging?
Jyoti Mayadev Case #2: Surgery vs CCRT for LACC
David Cibula Pro Surgery
Charles A. Leath III Pro Radiation: In view of the results of the Abrax trial, should we operate clinically node positive pts? What method is most reliable?
Jyoti Mayadev Addition systemic therapy to radiation (CCRT)
Bradley Monk Current status of definitive LACC clinical trials
Leslie Randall Case #3: Recurrent and Metastatic Disease 1L IO
Ana Oaknin Entering the Immunotherapy Era in Cervical Cancer: the seismic shift in the treatment landscape 
Leslie Randall Second-line metastatic disease case
Nicole Concin Turn on the TV!: Getting to know the antibody drug conjugate, tisotumab vedotin 
Leslie Randall The new dilemma of biomarkers for ICI and sequencing therapies in cervical cancer
Dmitriy Zamarin The new dilemma of biomarkers and sequencing IO and TV in cervical cancer

Master Session: Ovarian Cancer
Christina Fotopoulou Cutting Edge of Innovation: Surgery
Jalid Sehouli  Novel Surgical strategies and current major trial updates in ovarian cancer
Sudha Sundar Global challenges of the implementation of surgery for advanced disease
Marcela G. Del Carmen Oncologic and reproductive aspects of fertility sparing surgery in epithelial and non epithelial subtypes
Angeles Alvarez Secord Move over Chemotherapy: Exploring Systemic Therapeutic Options in Ovarian Cancer
Angeles Alvarez Secord Session introduction & survey
Rebecca Kristeleit Beyond PARPi Progression - What now?
David Tan Exploring Non-conventional Therapeutic Options
Angelica Nogueira-Rodrigues Real-World Challenges Accessing Novel Therapeutics
Clare Scott Role of prognostic and predictive Biomarkers in Ovarian cancer
Charlie Gourley  Biomarkers to direct surgical treatment - current landscape PREDICT OPTIMIZE OUTCOME
Rowan Miller Biomarkers to direct systemic treatment - Current landscape ESMO GUIDELINES
Alexandra Leary Biomarker future directions and clinical trials 

Master Session: Uterine Cancer
Xavier Matias-Guiu Molecular classification of endometrial cancer: a new challenge for the pathologist?
Xavier Matias-Guiu, Gian Franco Zannoni, Russell Broaddus, Tjalling Bosse Panel discussion
Domenica Lorusso Adjuvant treatment of endometrial cancer in 2021 and Beyond: How is it evolving?
Mansoor R. Mirza, Daniela Matei, Carien Cruetzberg Panel discussion
Brian Slomovitz Treatment of advanced and recurrent endometrial cancer: is chemotherapy passé?
Nicoletta Colombo, Ana Oaknin, Ronnie Shapira, David Tan Panel discussion

Master Session: Vulvar Cancer
Linda Nooij Translational research in vulvar cancer: from bench to the clinic within the next decade?
Giorgia Garganese Sentinel nodes in vulvar cancer: what remains to be explored after GROINSS V studies?
Nadia Dornhöfer Vulvar reconstruction by plastic surgery after treatment for primary and recurrent vulvar cancer
David Gaffney Role of (adjuvant) radiation therapy (margin status, one node vs. more than 1 node, recurrent disease)
Linn Woelber Distant recurrence: Medical treatment in advanced disease – silver lining on the horizon

Plenary I: Oral Abstract Presentation
Krishnansu S. Tewari Empower-cervical 1/GOG-3016/ENGOT-Cx9: Results Of Phase 3 Trial Of Cemiplimab Vs Investigator’s Choice Chemotherapy In Recurrent/Metastatic Cervical Carcinoma
Vicky Makker Randomized Phase 3 Study of Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer (Aec): Subgroup Analysis of Patients With DNA Mismatch Repair Deficient (Dmmr) Tumors
Ana Oaknin Antitumor Activity of Dostarlimab in Patients With Advanced or Recurrent Mismatch Repair–deficient or Proficient–cancer by Prior Therapy: Results from the Garnet Study
Antonio González-Martín Distillation

Plenary II: Oral Abstract Presentation
Paolo Zola Does Intensive Follow-Up Improve Overall Survival in Endometrial Cancer Patients? Results from the Totem Randomized Controlled Trailed
Giorgia Dinoi Where There is Smoke, There is Fire: Understanding the Implications of Positive Sentienel Lymph Nodes in Endometrial Cancer
Floor Backes Distillation
Liron Kogan Minimally Invasive Surgery in Advanced Endometrial Carcinoma is Associated with an Increased Risk for Local Recurrence
Bianca Reijntjes Recurrence and Survival After Laparoscopy Versus Laparotomy in Early-Stage Endometrial Cancer: Long-Term Outcomes of a Randomized Trial
Mario Leitao Distillation

Plenary III: Presidential Plenary
Robert Coleman Presidential Address
Robert Coleman, Marie Plante, Thomas Herzog, Mansoor Mirza, Alison Brand Panel discussion

Plenary IV: Oral Abstract Presentations
David O’Malley Mirvetuximab Soravtansine, A Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC), in Combination with Bevacizumab In Patients (PTS) with Platinum-Agnostic Ovarian Cancer - Final Analysis
Vicky Makker A Multicenter, Open-label, Randomized, Phase 3 Study To Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab vs Treatment of Physician's Choice in Patients with Advanced Endometrial Cancer: Study 309/Keynote-775
Rebecca Kristeleit Rucaparib Vs Chemotherapy in Patients with Advanced, Relapsed Ovarian Cancer and A Deleterious Brca Mutation: Efficacy and Safety from Ariel4, A Randomized Phase 3 Study
Kathleen Moore  Adjuvant Chemotherapy Following Chemo-radiation as Primary Treatment for Locally Advanced Cervical Cancer Compared To Chemo-radiation Alone: The Randomised Phase 3 OUTBACK Trial

Plenary V: Oral Abstract Presentations
Emily Thompson Prognostic Significance of ‘P53 Signature’ (Fields Of Dysplasia) and in Situ Margin Status in Organ-confined HPV-independent P53 Abnormal Vulvar Squamous Cell Carcinoma
Ting Wan Multi-omics Characterization of Molecular Features Correlated to Perineural Invasion in Cervical Cancer
Kathleen Moore  Distillation
Bradley Monk Tisotumab Vedotin (TV) + Bevacizumab Or Pembrolizumab or Carboplatin in Recurrent/metastatic Cervical Cancer (R/MCC): Phase 1b/2 ENGOT-Cx8/GOG-3024/Innovatv 205 Study Dose-Escalation Results
Jusheng An Efficacy and Safety of Socazolimab in Recurrent or Metastatic Cervical Cancer: Results from the Phase I Trial Followed by an Expansion Study
Leslie Randall Distillation

Plenary VI: Oral Abstract Presentations
Beryl Manning-Geist Comprehensive Genomic Profiling of Low-Grade Serous Cancers and Associated Clinical Outcomes
Robert Coleman Clinical and Molecular Characteristics Of Ariel3 Patients Who Derived Exceptional Benefit From Rucaparib Maintenance Treatment for High-Grade Ovarian Cancer (HGOC)
Yunong Gao Efficacy and Safety of Niraparib Maintenance Treatment in Platinum-Sensitive Recurrent Ovarian Cancer After Shorter Or Longer Chemotherapy: A Post Hoc Subgroup Analysis
Shannon Westin  Distillation
Member Benefit
This course is an IGCS member benefit.

Not an IGCS member? Join IGCS today and be a part of the leading global society advancing gynecologic cancer care around the world. In addition to complimentary valuable educational resources and training opportunities, you will also be supporting the society’s mission to enhance the care of women with gynecologic cancer worldwide through education and training and public awareness. Click here to learn more about IGCS member benefits.
Availability: On-Demand
Cost: FREE
Contact for assistance.
Powered By